| Sharit Saffati, | |
|
20700 W Dixie Hwy, Aventura, FL 33180-1146 | |
| (305) 933-5887 | |
| (305) 933-8991 |
| Full Name | Sharit Saffati |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 20700 W Dixie Hwy, Aventura, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306174826 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SZ4752 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sharit Saffati, 20700 W Dixie Hwy, Aventura, FL 33180-1146 Ph: (305) 933-5887 | Sharit Saffati, 20700 W Dixie Hwy, Aventura, FL 33180-1146 Ph: (305) 933-5887 |
News Archive
Researchers at the University of Adelaide have successfully trialed a new technique that could aid the process of choosing the "best" embryo for implantation, helping to boost the chances of pregnancy success from the very first IVF cycle.
A simple test to identify MRSA in wounds could identify the superbug quickly and help prevent infection from spreading.
Morderna has announced plans to develop a range of new mRNA-based vaccines against other viruses, including the influenza virus, human immunodeficiency virus (HIV), and the Nipah virus.
"Practice makes perfect" seems logical, but how much practice remains uncertain, and current health care quality guidelines may be set too high. It may be time to reexamine the standard recommending hospitals perform at least 400 angioplasty and stent procedures per year, according to a new study in the May 19, 2004 issue of the Journal of the American College of Cardiology.
Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.
› Verified 6 days ago
Dina Leah Schneck, MS, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20700 W Dixie Hwy, Aventura, FL 33180 Phone: 305-933-5887 | |
Debra Jennifer Beeferman, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 19501 E Country Club Dr Apt 204, Aventura, FL 33180 Phone: 305-936-1918 | |
Jillian Caballero, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20700 W Dixie Hwy, Aventura, FL 33180 Phone: 305-933-5887 | |
Jessica Desisto, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3330 Ne 190th St Apt 2114, Aventura, FL 33180 Phone: 774-487-2162 | |
Dr. Robin Bersson, PH.D.C.C.C. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20700 W Dixie Hwy, Aventura, FL 33180 Phone: 305-933-5887 | |
Bracha Roth, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 20505 E Country Club Dr Apt 934, Aventura, FL 33180 Phone: 718-986-5283 | |
Ana Maria Vanegas, SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3131 Ne 188th St Apt 1603, Aventura, FL 33180 Phone: 305-803-1835 |